Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Willem J. A. Witlox; Antoinette D. I. van Asselt; Robert Wolff; Nigel Armstrong; Gill Worthy; Annette Chalker; Titas Buksnys; Lisa Stirk; Jos Kleijnen; Manuela A. Joore; Sabine E. Grimm

doi:10.1007/s40273-019-00870-w

Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Willem J. A. Witlox^*, Antoinette D. I. van Asselt, Robert Wolff, Nigel Armstrong, Gill Worthy, Annette Chalker, Titas Buksnys, Lisa Stirk, Jos Kleijnen, Manuela A. Joore, Sabine E. Grimm

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

Original language	English
Pages (from-to)	317-324
Number of pages	8
Journal	Pharmacoeconomics
Volume	38
Issue number	4
Early online date	9 Dec 2019
DOIs	https://doi.org/10.1007/s40273-019-00870-w
Publication status	Published - Apr 2020

Access to Document

10.1007/s40273-019-00870-wLicence: CC BY-NC

Cite this

Witlox, W. J. A., van Asselt, A. D. I., Wolff, R., Armstrong, N., Worthy, G., Chalker, A., Buksnys, T., Stirk, L., Kleijnen, J., Joore, M. A., & Grimm, S. E. (2020). Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 38(4), 317-324. https://doi.org/10.1007/s40273-019-00870-w

Witlox, Willem J. A. ; van Asselt, Antoinette D. I. ; Wolff, Robert ; Armstrong, Nigel ; Worthy, Gill ; Chalker, Annette ; Buksnys, Titas ; Stirk, Lisa ; Kleijnen, Jos ; Joore, Manuela A. ; Grimm, Sabine E. / Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer : An Evidence Review Group Perspective of a NICE Single Technology Appraisal. In: Pharmacoeconomics. 2020 ; Vol. 38, No. 4. pp. 317-324.

@article{1488bf5aa1fb4ac492cf6908682afbe9,

title = "Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal",

author = "Witlox, {Willem J. A.} and {van Asselt}, {Antoinette D. I.} and Robert Wolff and Nigel Armstrong and Gill Worthy and Annette Chalker and Titas Buksnys and Lisa Stirk and Jos Kleijnen and Joore, {Manuela A.} and Grimm, {Sabine E.}",

year = "2020",

month = apr,

doi = "10.1007/s40273-019-00870-w",

language = "English",

volume = "38",

pages = "317--324",

journal = "Pharmacoeconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "4",

}

Witlox, WJA, van Asselt, ADI, Wolff, R, Armstrong, N, Worthy, G, Chalker, A, Buksnys, T, Stirk, L, Kleijnen, J , Joore, MA & Grimm, SE 2020, 'Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal', Pharmacoeconomics, vol. 38, no. 4, pp. 317-324. https://doi.org/10.1007/s40273-019-00870-w

Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer : An Evidence Review Group Perspective of a NICE Single Technology Appraisal. / Witlox, Willem J. A.; van Asselt, Antoinette D. I.; Wolff, Robert; Armstrong, Nigel; Worthy, Gill; Chalker, Annette; Buksnys, Titas; Stirk, Lisa; Kleijnen, Jos ; Joore, Manuela A.; Grimm, Sabine E.

In: Pharmacoeconomics, Vol. 38, No. 4, 04.2020, p. 317-324.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer

T2 - An Evidence Review Group Perspective of a NICE Single Technology Appraisal

AU - Witlox, Willem J. A.

AU - van Asselt, Antoinette D. I.

AU - Wolff, Robert

AU - Armstrong, Nigel

AU - Worthy, Gill

AU - Chalker, Annette

AU - Buksnys, Titas

AU - Stirk, Lisa

AU - Kleijnen, Jos

AU - Joore, Manuela A.

AU - Grimm, Sabine E.

PY - 2020/4

Y1 - 2020/4

U2 - 10.1007/s40273-019-00870-w

DO - 10.1007/s40273-019-00870-w

M3 - Review article

VL - 38

SP - 317

EP - 324

JO - Pharmacoeconomics

JF - Pharmacoeconomics

SN - 1170-7690

IS - 4

ER -